Aurobindo Pharma Approves Merger of Two Wholly Owned Subsidiaries

Aurobindo Pharma Ltd's board has approved a Scheme of Amalgamation for merging its wholly owned subsidiaries, Auroactive Pharma Private Limited with Apitoria Pharma Private Limited. Both companies are involved in the manufacture of active pharmaceutical ingredients (APIs). The merger aims to consolidate API businesses under a single entity, improve operational efficiency, optimize capacity utilization, and simplify the group's corporate structure. The transaction is conducted at an arm's length price based on an independent valuation report and is exempt from certain SEBI regulations as it involves wholly owned subsidiaries. The share exchange ratio involves issuing 97 equity shares of Apitoria Pharma for every 10,000 equity shares of Auroactive Pharma. The company's shareholding pattern remains unchanged.